Trial Profile
An open-label, 2-way crossover study of steady-state intragastric pH control comparing 2 dosage regimens of esomeprazole and lansoprazole in Barrett's esophagus patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2009
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary) ; Lansoprazole (Primary)
- Indications Barrett's oesophagus; Gastro-oesophageal reflux
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 17 Jul 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
- 19 Jun 2007 Status changed from in progress to completed.
- 14 Oct 2006 New trial record.